Efficacy and Safety of Text Messages Targeting Adherence to Cardiovascular Medications in Secondary Prevention: TXT2HEART Colombia Randomized Controlled Trial (Preprint)
Authors: Bermon Anderson , Uribe Ana Fernanda , Pérez-Rivero Paula Fernanda , Prieto-Merino David , Saaibi Jose Federico , Silva Federico Arturo , Canon Diana Ivonne , Castillo-Gonzalez Karol Melissa , Cáceres-Rivera Diana Isabel , Guio Elizabeth , Meneses-Castillo Karen Janneth , Castillo-Meza Alberto , Atkins Louise , Horne Robert , Murray Elizabeth , Serrano Norma Cecilia , Free Caroline , Casas Juan Pablo , Perel Pablo 
Published: November 2020

BACKGROUND

Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide, with a prevalence of approximately 100 million patients. There is evidence that antiplatelet agents and antihypertensive medications could reduce the risk of new vascular events in this population; however, treatment adherence is very low. An SMS text messaging intervention was recently developed based on behavior change techniques to increase adherence to pharmacological treatment among patients with a history of ASCVD.

OBJECTIVE

This study aims to evaluate the efficacy and safety of an SMS text messaging intervention to improve adherence to cardiovascular medications in patients with ASCVD.

METHODS

A randomized controlled clinical trial for patients with a prior diagnosis of cardiovascular events, such as acute myocardial infarction, unstable angina, cerebrovascular disease, or peripheral artery disease, in one center in Colombia was conducted. Patients randomized to the intervention arm were assigned to receive SMS text messages daily for the first 4 weeks, 5 SMS text messages on week 5, 3 SMS text messages each in weeks 6 and 7, and 1 SMS text message weekly from week 8 until week 52. In contrast, patients in the control arm received a monthly SMS text message reminding them of the next study appointment and the importance of the study, requesting information about changes in their phone number, and thanking them for participating in the study. The primary endpoint was the change in low-density lipoprotein cholesterol (LDL-C) levels, whereas the secondary endpoints were the changes in thromboxane B2 levels, heart rate, systolic and diastolic blood pressure, medication adherence, cardiac and noncardiac mortality, and hospitalization. Linear regression analyses and bivariate tests were performed.

RESULTS

Of the 930 randomized patients, 805 (86.5%) completed follow-up and were analyzed for the primary endpoint. There was no evidence that the intervention changed the primary outcome (LDL-C levels; <i>P</i>=.41) or any of the secondary outcomes evaluated (all <i>P</i>&gt;.05). There was also no evidence that the intervention was associated with adverse events.

CONCLUSIONS

In this study, there was no evidence that a behavior modification intervention delivered by SMS text messaging improved LDL-C levels, blood pressure levels, or adherence at 12 months. More research is needed to evaluate whether different SMS text messaging strategies, including personalized messages and different timings, are effective; future studies should include mixed methods to better understand why, for whom, and in which context (eg, health system or social environment) SMS text messaging interventions work (or not) to improve adherence in patients with ASCVD.

CLINICALTRIAL

ClinicalTrials.gov NCT03098186; https://clinicaltrials.gov/ct2/show/NCT03098186

INTERNATIONAL REGISTERED REPORT

RR2-10.1136/bmjopen-2018-028017